



touchREVIEWS in RMD

VOLUME 1 • ISSUE 1 • 2022

EDITOR-IN-CHIEF: PETER TAYLOR

The Role of Interleukin-23 Inhibition in the Treatment of Psoriatic Arthritis

Kate E Findeisen, Andrew JK Östör

Janus Kinase Inhibitor Selectivity in Rheumatoid Arthritis: Where Do We Stand?

Jérôme Avouac

Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis

Matthew J Mandell, Gatr-Alnada Gheriani, Aleksander Lenert, Petar S Lenert

Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus

Hannah E Gulko, Richard Furie

www.touchIMMUNOLOGY.com

touchREVIEWS in RMD

Volume 1 • Issue 1

touchREVIEWS in RMD is an international, peer-reviewed, free-to-access journal developed for touchIMMUNOLOGY.com

Editor-in-Chief

Peter Taylor

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

touchIMMUNOLOGY Expert Faculty

Richard Furie

Division of Rheumatology, Northwell Health and Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

Clive Kelly

University of Newcastle-upon-Tyne, Newcastle, UK

David McLain

McLain Medical Associates, Birmingham, AL, USA

Arthur Kavanaugh

Center for Innovative Therapy, University of California, San Diego, CA, USA

Maria-Antonietta D'Agostino

Versailles-Saint-Quentin University and University Hospital Ambroise Paré, Boulogne-Billancourt, France

Elena Nikiforou

Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK

Jérôme Avouac

Université de Paris, Hôpital Cochin, Service de Rhumatologie, Paris, France

Petar Lenert

Division of Immunology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Christopher Griffiths

Dermatology Centre, Barnes Building, Salford Royal NHS Foundation Trust, Manchester, UK

Su Lwin

Genetic Skin Disease Group, St John's Institute of Dermatology, King's College London, London, UK

Tiago Torres

Centro Hospitalar, Universitário do Porto, Porto, Portugal

Adam Reich

University of Rzeszow, Rzeszów, Poland

Sarosh Irani

Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Eva Monoz Couselo

Vall d'Hebron Hospital, Barcelona, Spain

Kevan Herold

Yale School of Medicine, New Haven, CT, USA

Gil Y Melmed

Inflammatory Bowel and Immunobiology Research Institute, and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Maria Oliva-Hemker

Johns Hopkins University School of Medicine, Baltimore, MD, USA

William Damsky

Yale School of Medicine, New Haven, CT, USA

Marcus Maurer

Department of Dermatology and Allergy and Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany

touchIMMUNOLOGY.com wishes to thank the organisations below for their assistance. This does not constitute any official endorsement.



www.touchmedicalmedia.com

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2022 Touch Medical Media Group Holdings Ltd, is a private limited company registered in England and Wales at Lancashire Gate, 21 Tiviot Dale, Stockport, Cheshire, SK1 1TD, UK, with registered number 08197142. All rights reserved. eISSN 2635-1420

touchREVIEWS

in RMD

Established: January 2021 Frequency: Bi-annual

Current edition: Volume 1 Issue 1

Aims and Scope

- *touchREVIEWS in RMD* enables time-pressured physicians to stay abreast of major advances and opinion in international rheumatology practice.
- *touchREVIEWS in RMD* comprises balanced and comprehensive articles, addressing the most important and salient developments in the field of rheumatology.
- *touchREVIEWS in RMD* endeavours to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
- Comprehensive bibliographies for each article mean that *touchREVIEWS in RMD* is an informative and valuable reference tool for use throughout the year.
- All articles are subject to peer review, and must adhere to the ICMJE, GPP-3, and COPE guidelines.

Structure and Format

- *touchREVIEWS in RMD* is a peer-reviewed, free-to-access, bi-annual journal comprising expert interviews, review articles, editorials, special reports and original research.
- The structure of each edition of the publication comprises section categories determined by the Managing Editor. The degree of coverage assigned to each category is the decision of the Managing Editor, and in part reflects the views of the Editorial Board.
- All articles disclose any author disclosures along with any funding, financial support, and medical writing assistance.
- Each edition of *touchREVIEWS in RMD* is published in full online at www.touchIMMUNOLOGY.com

Editorial Expertise

touchREVIEWS in RMD is supported by various levels of expertise:

- Guidance from an Editorial Board consisting of leading authorities from a variety of disciplines in immunology.
- Invited contributors who are recognised authorities from their respective fields.
- Peer review – conducted by experts appointed for their experience and knowledge of a specific topic.
- An experienced team of editors and technical editors.

Peer Review

- On submission, all articles are assessed by the Managing Editor to determine their suitability for inclusion and appropriateness for peer review.
- The Managing Editor identifies at least two appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area, following consultation with a member of the Editorial Board where necessary.

- We aim to have the final peer review decision within 4 weeks.
- Following review, papers are either accepted without modification, returned to the author(s) to incorporate required changes or not accepted for publication.
- The Managing Editor reserves the right to accept or reject any proposed amendments on the advice of the Editorial Board and reviewers.

Submissions and Instructions for Authors

- The Managing Editor commissions articles with guidance from the Editorial Board and unsolicited articles are welcomed.
- The Managing Editor is always keen to hear from authors wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Managing Editor for further details.
- The 'Instructions for Authors' information is available for download at www.touchIMMUNOLOGY.com

Distribution and Readership

touchREVIEWS in RMD is distributed bi-annually through controlled circulation to healthcare and pharmaceutical professionals in the field internationally.

Free-to-access

All articles are free-to-access, which allows everyone in the immunology field to download published articles for free.


Online

www.touchmedicalmedia.com provides clinicians and other industry professionals with a free resource of articles from over nine titles, spanning seven therapy areas including cardiology, endocrinology, immunology, neurology, oncology, ophthalmology and respiratory.

Society Partners

touchIMMUNOLOGY.com has developed very valuable society partnerships with the most respected not-for-profit medical societies internationally. These partnerships are key as touchIMMUNOLOGY.com helps to promote awareness of these medical societies while also providing free-to-access, peer-reviewed articles and multimedia content to the society members, which ensures that the community is kept up-to-date with the latest cutting-edge content and opinion from world-renowned doctors.

About Touch Medical Media

Touch Medical Media publishes a rich and diverse portfolio of free-to-access, peer-reviewed journals across the clinical and pharmaceutical arenas. Touch Medical Media aims to assist in the education and practice of healthcare and pharmaceutical professionals. 






touchTM
IMMUNOLOGY

Unlocking the pathogenesis of **chronic spontaneous urticaria**

This activity is funded by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.



What do the data from **AAAAI 2022** tell us about improving outcomes for patients with **EoE**?

“The ultimate goal is
bringing new treatments
to our patients with EoE
and improving their
symptoms and quality
of life going forward.”



DR EVAN DELLON



Minimizing the clinical burden of **chronic rhinosinusitis with nasal polyps**



This activity is funded by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touch IME.

Contents



Foreword

1 Foreword

Peter C Taylor

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

Letter from the Editor-in-Chief

2 Letter from the Editor-in-Chief

Peter C Taylor

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

Editorials

Fibromyalgia

3 The Links Between Fibromyalgia, Hypermobility and Neurodivergence

Clive Kelly,^{1,2} Ren Martin³ and Vadivelu Saravanan⁴

1. James Cook University Hospital, Middlesbrough, UK; 2. Newcastle University, Newcastle, UK; 3. Adolescent Autism Unit, Middlesbrough, UK; 4. Queen Elizabeth Hospital, Gateshead, UK

Rheumatoid Arthritis

5 Janus Kinase Inhibitor Selectivity in Rheumatoid Arthritis: Where Do We Stand?

Jérôme Avouac

Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France

Rheumatic Diseases

7 The Role of Self-management in Inflammatory Arthritis

Elena Nikiphorou

King's College London, London, UK

Reviews

Axial Spondyloarthritis

9 Comprehensive Review Exploring Novel Treatments for Psoriatic Arthritis and Axial Spondyloarthritis from 2016 to 2021

Amandeep Rakhra and Stephanie Mathew

Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

Psoriatic Arthritis

18 The Role of Interleukin-23 Inhibition in the Treatment of Psoriatic Arthritis

Kate E Findeisen¹ and Andrew JK Östör^{2,3}

1. Royal Melbourne Hospital, Melbourne, Victoria, Australia; 2. Cabrini Medical Centre, Melbourne, Victoria, Australia; 3. Monash University, Melbourne, Victoria, Australia

Contents



Reviews

Rheumatic Diseases

23 Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis**Matthew J Mandell, Gatr-Alnada Gheriani, Aleksander Lenert and Petar S Lenert***Division of Immunology, Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA*

Systemic Lupus Erythematosus

29 Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus**Hannah E Gulko and Richard Furie***Division of Rheumatology, Northwell Health, Great Neck, NY, USA***32 Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis****Yoshiya Tanaka***The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan*

**VIEW
DOWNLOAD
SUBSCRIBE
FREE**

